Hubei Goto Biopharm Revenue

In the year 2025, Hubei Goto Biopharm had annual revenue of 606.18M CNY with 12.97% growth. Hubei Goto Biopharm had revenue of 151.11M in the quarter ending December 31, 2025, a decrease of -11.74%.

Revenue

606.18M

Revenue Growth

+12.97%

P/S Ratio

4.75

Revenue / Employee

741.96K

Employees

817

Market Cap

2.88B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	606.18M	69.58M	12.97%
Dec 31, 2024	536.60M	-29.80M	-5.26%
Dec 31, 2023	566.40M	-38.17M	-6.31%
Jan 1, 2023	604.57M	13.69M	2.32%
Jan 1, 2022	590.89M	122.77M	26.23%
Dec 31, 2020	Pro	Pro	Pro
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Shandong Sito Bio-technology	954.76M
Jiangsu Sihuan Bioengineering	381.71M
Jilin Jian Yisheng Pharmaceutical	659.66M
Suzhou Fushilai Pharmaceutical	412.51M
Cabio Biotech (Wuhan)	418.18M
Shanghai Universal Biotech	1.07B
Landfar Bio-medicine	415.94M
Shanghai Model Organisms Center	421.02M

Revenue Rankings